Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Weekly Picks
Citigroup
CH
ChadWisperer
Community Contributor
Pole position to benefit from GENIUS Act
The passing of the GENIUS Act establishes a clear regulatory framework for stablecoins, allowing banks like Citi to issue their own stablecoins; Citi Token Services lets Citi position itself as the "killer app" for institutional cross-border payments, absorbing complexities and offering instant, cost-effective solutions; Core business is firing on all cylinders , with record performances in Markets and Wealth, significant share gains in Investment Banking (especially M&A, LevFin, and sponsors), and robust growth in Services and U.S. Personal Banking, all contributing to strong revenue momentum; Highly capital efficient returning $3 billion in capital during the quarter , including $2 billion in share repurchases, part of our $20 billion repurchase plan with a goal of 11% Return on tangible equity (ROTE or ROTCE). ✨ Chat with this narrative: https://notebooklm.google.com/notebook/aa2a6c92-6bd1-495e-beb5-d8d4e6525410 (believe a Google account is required) Background Citigroup Inc.
View narrative
US$233.04
FV
58.8% undervalued
intrinsic discount
6.00%
Revenue growth p.a.
Set Fair Value
16
users have liked this narrative
0
users have commented on this narrative
35
users have followed this narrative
7 days ago
author updated this narrative
IREN
KA
kapirey
Community Contributor
IREN will transform from bitcoin miner to leader in AI infrastructure
Key Highlights Financial Performance (Q3 FY25) Record Revenue : $148.1 million Record Adjusted EBITDA : $83.3 million Record EBITDA : $82.7 million Profit After Tax : $24.2 million Avg. Operating Hashrate : 29.4 EH/s Strong Margins : All-in cash cost per BTC mined at $41k vs.
View narrative
US$21.48
FV
17.5% undervalued
intrinsic discount
49.99%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
1
users have commented on this narrative
34
users have followed this narrative
Updated
narrative
XRF Scientific
RO
Robbo
Community Contributor
Behind the Assay: XRF Scientific’s Role in Modern Mining Economics
There’s an old saying that in a gold rush, those who make the money are the ones selling the shovels; and mining service companies have indeed proven to be shrewd investments historically. XRF Scientific holds a strong niche in sample preparation equipment and consumables used in X-ray fluorescence (XRF) and X-ray diffraction (XRD) analysis, which are essential in determining the quality and purity of materials.
View narrative
AU$2.10
FV
2.4% undervalued
intrinsic discount
9.68%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
7 days ago
author updated this narrative
All companies
Popular
Undervalued
Overvalued
Community Investing Ideas
Load previous narratives
Berkshire Hathaway
DA
davidlsander
Community Contributor
Berkshire Hathaway: A Fortress of Financial Strength
Berkshire Hathaway: A Fortress of Financial Strength Berkshire Hathaway, the investment conglomerate led by the legendary Warren Buffett, has long been admired for its disciplined investment strategy, long-term focus, and unwavering commitment to shareholder value. As the company prepares for the eventual transition of leadership to Greg Abel, it's essential to examine its financial strength and prospects for continued success.
View narrative
US$943.79k
FV
23.1% undervalued
intrinsic discount
13.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
6
users have commented on this narrative
33
users have followed this narrative
9 months ago
author updated this narrative
Emirates Reem Investments Company P.J.S.C
AB
AbidIlahi
Community Contributor
Bullish sentiment - Exceptional industry growth and firm overperformed its peers
https://www.linkedin.com/in/abidilahi03/ The recent rise in stock value seems to exclusively be investor sentiment and outlook. Excluding the attractive 0% Debt-to-Equity ratio of ERC and earnings report it is to note that ERC has outperformed its industry.
View narrative
د.إ2.15
FV
33.0% overvalued
intrinsic discount
2.00%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
9 months ago
author updated this narrative
Alphabet
RY
rynetmaxwell
Community Contributor
Google Search Continues to Dominate + Google Cloud Grows
Meaning During the tech bubble of the late 90’s, Larry Page and Sergey Brin founded Google which later went public in 2004. Larry and Sergey’s founding motto, “Google is not a conventional company.
View narrative
US$183.95
FV
5.0% overvalued
intrinsic discount
10.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
9 months ago
author updated this narrative
CVS Health
YI
yiannisz
Community Contributor
Why CVS’s Valuation Signals Opportunity
CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connected with its Medicare and Individual Exchange businesses and a whopping $1.2 billion restructuring charge for store closures.
View narrative
US$103.00
FV
41.1% undervalued
intrinsic discount
18.02%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
9
users have commented on this narrative
98
users have followed this narrative
9 months ago
author updated this narrative
Enphase Energy
GO
Goran_Damchevski
Equity Analyst
Market Leadership Amidst Increasing Competition Won't Hurt Solid Revenue Growth
Key Takeaways Electricity prices, incentives (tax credits, net metering) and technology advancements will drive sales. Microinverters are gaining traction but their advantage over traditional inverters is unclear.
View narrative
US$76.86
FV
53.9% undervalued
intrinsic discount
24.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
11
users have followed this narrative
9 months ago
author updated this narrative
Tesla
GO
Goran_Damchevski
Equity Analyst
Decent Revenue Growth Won't Stop Valuation Multiple Re-rating Lower
Key Takeaways Tesla’s auto market share will grow but less than investors expect The semi will contribute $17.5B if its value proposition matches that of ICE trucks Energy revenues will reach $16.7B in 2028 as industry tailwinds support continued growth If FSD wins, it’s at risk of being shared by government safety mandates PE will re-rate lower in long term to be similar to current auto peers Business has great growth prospects, but even they don’t justify current price Catalysts Tesla’s TAM and Market Share Has Limitations In the last 4 quarters ending Q2’23, Tesla has delivered 1,638,123 vehicles. Approximately 46.8% of total sales are made in the U.S. and we can use this as a basis to estimate the number of vehicles sold in the U.S., which comes out to 766,478.
View narrative
US$177.19
FV
78.4% overvalued
intrinsic discount
14.36%
Revenue growth p.a.
Set Fair Value
113
users have liked this narrative
18
users have commented on this narrative
27
users have followed this narrative
9 months ago
author updated this narrative
Starbucks
GO
Goran_Damchevski
Equity Analyst
International Store Growth To Sustain Revenue Growth Despite Labour Headwinds
Key Takeaways Store growth plans to increase by 74% internationally, but only 12% in the US. Coffee demand is expected to be a tailwind for revenues longer term, growing at a stable 4.2%.
View narrative
US$86.27
FV
9.4% overvalued
intrinsic discount
5.00%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
4
users have commented on this narrative
9
users have followed this narrative
9 months ago
author updated this narrative
Johnson & Johnson
GO
Goran_Damchevski
Equity Analyst
Rich Drug Pipeline Will Push Revenues and Earnings Higher
Key Takeaways Well-diversified drug pipeline with 52 drugs in late-stage approval - a good hedge for its patent expirations Kenvue spin off allows JNJ to focus on its more profitable Medical Devices and Pharmaceuticals segments Continued dividend increases and buybacks are affordable and will help capital returns Post Kenvue, I expect JNJ to grow revenues by 7.5% p.a. from its new baseline of $84B, and at higher margins Some risks around litigation, patent expiry and drug success are present Catalysts Robust Drug Pipeline: 52 Drugs Racing To The Finish Line In Late-Stage Approval The key threat to a pharmaceutical stock is the patent expiration of their high value assets. Should a company lack a product pipeline to bolster its future product portfolio, then losing exclusivity to any one drug can be a hit to the business.
View narrative
US$173.55
FV
3.0% undervalued
intrinsic discount
6.30%
Revenue growth p.a.
Set Fair Value
16
users have liked this narrative
1
users have commented on this narrative
21
users have followed this narrative
9 months ago
author updated this narrative
Rheinmetall
DE
DenisH
Community Contributor
Defense growth potential.
WHY? Rheinmetall’s stock could justify a valuation of $430 due to its strategic positioning in the defense and automotive industries, particularly as global defense spending rises amidst growing geopolitical tensions.
View narrative
€420.00
FV
312.9% overvalued
intrinsic discount
1.38%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
9 months ago
author updated this narrative
Value any company in seconds
Popular companies